PHASQ Stock Crashes 99% on Pink Sheets, Bankruptcy Aftermath

PHASQ stock has collapsed to near-zero levels, trading at just $0.000001 USD on the Pink Sheets (PNK) exchange as of April 30, 2026. The PHASQ stock price reflects the devastating aftermath of PhaseBio Pharmaceuticals’ Chapter 11 bankruptcy filing in October 2022. Once a clinical-stage biopharmaceutical company developing cardiovascular treatments, PhaseBio has seen its equity value essentially wiped out. The stock has declined 99% from its previous close of $0.0001, with trading volume at just 2,500 shares compared to an average of 22,310. This represents one of the most severe collapses in biotech history, leaving shareholders with minimal recovery prospects.

What Happened to PHASQ Stock and PhaseBio

PhaseBio Pharmaceuticals filed for voluntary reorganization under Chapter 11 bankruptcy on October 23, 2022, in the U.S. Bankruptcy Court for the District of Delaware. The company, based in Malvern, Pennsylvania, had been developing novel cardiovascular treatments including bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor in Phase III clinical trials.

The bankruptcy filing marked the end of the company’s independent operations. Despite having 600 full-time employees at its peak, PhaseBio could not sustain operations or secure adequate funding. The PHASQ stock now trades on the Pink Sheets, a venue for distressed and delisted securities where price discovery becomes extremely difficult.

PHASQ Stock Price Metrics and Trading Activity

The current PHASQ stock price sits at $0.000001 USD, representing a 99% decline from the previous close. The stock has not recovered since the bankruptcy announcement, with a year-high of just $0.0399 and a year-low matching the current price.

Trading volume remains extremely thin at 2,500 shares, well below the 22,310-share average volume. The 50-day moving average stands at $0.000236, while the 200-day average is $0.000666. These metrics indicate virtually no institutional interest and minimal liquidity. Track PHASQ on Meyka for real-time updates on this distressed security.

Financial Deterioration and Negative Metrics

PhaseBio’s financial position has deteriorated severely. The company reports negative earnings per share (EPS) of -$2.14, with a negative price-to-earnings ratio reflecting ongoing losses. Operating cash flow per share stands at -$1.61, while free cash flow per share is -$1.70, indicating the company continues burning cash.

The company’s book value per share is negative at -$3.16, suggesting liabilities exceed assets. Market capitalization has collapsed to zero, and the enterprise value is negative at -$33.96 million. These metrics confirm PhaseBio has no viable equity value remaining for shareholders.

Market Sentiment and Liquidation Status

Trading Activity: The Pink Sheets market shows virtually no trading interest in PHASQ. Daily volume of 2,500 shares represents an 88.8% decline from average volume, indicating most shareholders have abandoned the position or cannot find buyers.

Liquidation Outlook: With bankruptcy proceedings ongoing and negative enterprise value, the company faces complete equity wipeout. Creditors will be prioritized in any liquidation, leaving common shareholders with zero recovery. The stock’s continued trading reflects only speculative interest from distressed-security traders seeking any potential recovery, however remote.

Final Thoughts

PHASQ stock exemplifies biotech investment failure. Trading at $0.000001 after PhaseBio’s October 2022 bankruptcy, the stock lost 99% of its value. The company’s clinical-stage pipeline, including bentracimab, failed to generate revenue or secure funding. Negative earnings, cash flow, and book value confirm total equity destruction. Shareholders face zero recovery as creditors take priority. This case demonstrates extreme risks in clinical-stage biotech where regulatory approval and funding are never guaranteed. Investors should avoid distressed Pink Sheets securities without understanding bankruptcy and recovery processes.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.